Pelthos Therapeutics elects directors and approves new equity plan at annual meeting

Pelthos Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on Monday, where stockholders voted on three proposals, including the election of directors, the ratification of the company’s independent auditor, and the approval of a new equity incentive plan. All eight nominees for the board of directors were elected to serve until the 2027 Annual Meeting or until successors are elected and qualified.

The Pelthos Therapeutics Inc. 2026 Equity Incentive Plan, which replaces the company’s 2023 Equity Incentive Plan, was also approved by the stockholders. Despite recent volatility, InvestingPro analysis suggests the stock appears undervalued at current levels, placing it among opportunities on the platform’s Most Undervalued list.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.